




Daily case numbers per 100,000 population
(seven day average)



Daily fatalities per 100,000 population
(seven day average)




England, estimate of weekly rate of new cases per 100,000 population, by age group from testing data.



Data from Public Health England, Pillar 1 and 2 data, 18 September. Contains National Statistics data including 2018 population, Crown Copyright and Database Copyright 2020. Note that these numbers are based on testing. The ONS survey data support that prevalence and incidence has increased

If doubling occurred every seven days what would it look like?



Data before 15 September represents reported cases from UK by reporting date (Public Health England).


Example scenario after 15 September assumes for the purposes of illustration only a seven day doubling time between 15 September and 13 October

Fewer than 8% of people overall have developed antibodies to the virus


Study	ONS	REACT-2, Round 1	Biobank	NHSBT
Testing period	26 April – 8 Sept	20 June – 13 July	27 May – 6 July	16 Aug
Percentage of people testing positive for antibodies to SARS-CoV-2	6.2 %	6.0 %	7.1 %	5.5 %

Geographical spread of COVID-19 in England


Total Rate (per 100,000 population) of Pillar 1 & 2 Lab-Confirmed COVID-19 Cases in 7 days up to 09/09/20




Change of Rate (per 100,000 population) of Pillar 1 & 2 Lab-Confirmed COVID-19 Cases between 7 days up to 09/09/20 and previous 7 days



Estimated new COVID-19 inpatient cases in England



Progress on vaccines



London School of Hygiene and Tropical Medicine: Vaccine landscape

UK has also committed to join COVAX:
An international initiative supporting discovery, manufacture and fair distribution of Covid-19 vaccines worldwide

Vaccines with UK Supply Agreements	
Vaccine Type	Vaccine Developer
mRNA	BioNTech/ Pfizer
Adenoviral	Oxford/ AstraZeneca
	Janssen
Protein Adjuvant	Novavax
	GlaxoSmithKline/ Sanofi Pasteur
Inactivated Whole Virus	Valneva
Prophylactic neutralising antibodies	AstraZeneca